



1644
\$

PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00

Complete if Known

Application Number	09/855,717
Filing Date	May 16, 2001
First Named Inventor	NABIL HANNA
Examiner Name	Phillip Gambel
Art Unit	1644
Attorney Docket No.	037003-0280623

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number: 033975
Deposit Account Name: PILLSBURY WINTHROP LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)					(\$ 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below		Fee Paid
Total Claims	<input type="text"/>	-20** =	<input type="text"/>	X	<input type="text"/>	<input type="text"/>
Independent Claims	<input type="text"/>	-3** =	<input type="text"/>	X	<input type="text"/>	<input type="text"/>
Multiple Dependent					<input type="text"/>	<input type="text"/>

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	86	2201	43	Independent claims in excess of 3	
1203	290	2203	145	Multiple dependent claim, if not paid	
1204	86	2204	43	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					(\$ 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	
Other fee (specify)					
*Reduced by Basic Filing Fee Paid					
SUBTOTAL (3)					(\$ 180.00

SUBMITTED BY

Name (Print/Type)	Thomas A. Cawley	Registration No. (Attorney/Agent)	40944	Telephone	(703) 905-2144
Signature		Date	April 28, 2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Docket Number: 037003-0280623
Client Reference: 1999-30-0466CP3



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re The Application of HANNA et al.	Group Art Unit: 1644
Application No.: 09/855,717	Examiner: Phillip Gambel
Filed: May 16, 2001	Confirmation No.: 9413
For: TREATMENT OF B CELL MALIGNANCIES USING COMBINATION OF B CELL DEPLETING ANTIBODY AND IMMUNE MODULATING ANTIBODY RELATED APPLICATIONS	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is submitted herewith. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first official action on the merits, but before the mailing date of a final rejection or notice of allowance. Payment of the requisite fee under 37 CFR 1.17(p) is enclosed.

Respectfully submitted,

Thomas A. Cawley, Jr., Ph.D.
Registration Number 40,944

04/28/2004 ZICHARI 00000003 033975 09855717
21 50-1505 100.00 DR

Date: April 28, 2004
PILLSBURY WINTHROP LLP
Telephone: (703) 905-2000
Facsimile: (703) 905-2500
P.O. Box 10500
McLean, VA 22102
TAC/JBM:ntb

APR 28 2004

Atty. Dkt. No.
037003-0280623Client Ref.
1999-30-0466CP3

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: NABIL HANNA et al.

Appln. No.: 09/855,717

Filing Date: May 16, 2001

Date: April 28, 2004

Page 1 of 4

Examiner: Phillip Gambel

Group Art Unit: 1644

U.S. PATENT DOCUMENTS


Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	2001/0018041A1	08/2002	Hanna			
	BR	5,443,953	08/1995	Hansen			
	CR	5,484,892	01/1996	Tedder			
	DR	5,500,362	03/1996	Robinson			
	ER	5,595,721	01/1997	Kaminski			
	FR	5,674,492	10/1997	Armitage			
	GR	5,677,165	10/1997	de Boer			
	HR	5,677,180	10/1997	Robinson			
	IR	5,681,722	10/1997	Newman			
	JR	5,686,072	11/1997	Uhr			
	KR	5,750,105	05/1998	Newman			
	LR	5,736,137	04/1998	Anderson			
	MR	5,747,037	05/1998	Noelle			
	NR	5,776,456	07/1998	Anderson			
	OR	5,789,554	08/1998	Morita			
	PR	5,801,227	09/1998	Fanslow			
	QR	5,821,337	10/1998	Carter			
	RR	5,869,050	02/1999	de Boer			
	SR	5,874,082	02/1999	de Boer			
	TR	5,874,085	02/1999	Mond			
	UR	5,876,718	03/1999	Noelle			
	VR	5,885,577	03/1999	Alvarez			
	WR	5,945,513	08/1999	Aruffo			
	XR	6,011,138	01/2000	Reff			
	YR	6,113,898	09/2000	Anderson			

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract	Translation Readily Available
	ZR	WO 95/06666	03/1995	PCT	Noelle			
	AAR	WO 96/12741	05/1996	PCT	Bonnefoy			
	BBR	WO 98/41641	09/1998	PCT	Fitzgerald			
	CCR	WO 98/42378	10/1998	PCT	Goldenberg			
	DDR	WO 98/56418	12/1998	PCT	Lam			
	EER	WO 00/20864	04/2000	PCT	Barbera-Guillem			
	FFR	555 880 A2	08/1993	EP	Aruffo			


OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

GGR Abaza MS et al., "Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin," *J Protein Chem*, 1992, 11: 433-444.



	HHR ✓	Anderson D et al., "A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4," <i>Clin Immunol Immunopathol</i> , 1997, 84: 73-84.
	IIR ✓	Benoit NE et al., "Increased inhibition of proliferation of human B cell lymphomas following ligation of CD40, and either CD19, CD20, CD95 or surface immunoglobulin," <i>Immunopharmacology</i> , 1996, 35: 129-139.
	JJR ✓	Berinstein NL et al., "Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma," <i>Ann Oncol</i> , 1998, 9: 995-1001.
	KKR ✓	Bohlen H et al., "Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies," <i>Cancer Res</i> , 1993, 53: 4310-4314.
	LLR	Brams P et al., "A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation," <i>Int Immunopharmacol</i> , 2001, 1: 277-294.
	MMR ✗	Byrd JC et al., "The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction," <i>Blood</i> , 2002, 99: 1038-1043 (abstract only).
	NNR ✓	Campana D et al., "Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue," <i>J Immunol</i> , 1985, 134: 1524-1530.
	OOR ✗	Carbone A et al., "Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines," <i>Blood</i> , 1995, 85:780-789.
	PPR ✓	Clodi K et al., "Unbalanced expression of Fas and CD40 in mantle cell lymphoma," <i>Br J Haematol</i> , 1998, 103: 217-219.
	QQR ✓	Clynes R et al., "Fc receptors are required in passive and active immunity to melanoma," <i>Proc Natl Acad Sci USA</i> , 1998, 95: 652-656.
	RRR +	Coiffier B et al., "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study," <i>Blood</i> , 1998, 92: 1927-1932.
	SSR ✓	Czuczman MS et al., "Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy," <i>J Clin Oncol</i> , 1999, 17: 268-276.
	TTR	Demidem A et al., "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs," <i>Cancer Biother Radiopharm</i> , 1997, 12: 177-186.
	UUR	Endo K, "[Current status of nuclear medicine in Japan]," <i>Gan To Kagaku Ryoho</i> , 1999, 26: 744-748.
	VVR —	Engel P et al., "Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand," <i>J Exp Med</i> , 1995, 181: 1581-1586.
	WWR —	Flores-Romo L et al., "Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23," <i>Science</i> , 1993, 241:1038-1046.
	XXR	Fournier S et al., "CD23 antigen regulation and signaling in chronic lymphocytic leukemia," 1992, <i>J Clin Invest</i> , 89:1312-1321.
	YYR —	Funakoshi S et al., "Inhibition of human B-cell lymphoma growth by CD40 stimulation," <i>Blood</i> , 1994, 83: 2787-2794.
	ZZR ✓	Green KA et al., "Evidence for a continued requirement for CD40/CD40 ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS," <i>Virology</i> , 1998, 241: 260-268.
	AAAR ✓	Griggs ND et al., "The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells," <i>J Exp Med</i> , 1996, 183(3):801-810.
	BBBR —	Grossbard ML et al., "Monoclonal antibody-based therapies of leukemia and lymphoma," <i>Blood</i> , 1992, 80: 863-878.
	CCCR ✓	Johnson PW et al., "Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system," <i>Blood</i> , 1993, 82: 1848-1857.
	DDDR —	Kano Y et al., "In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis," 2000, <i>Leukemia</i> , 14(3):379-88.
	EEER —	Kiesel S et al., "Removal of cells from a malignant B-cell line from bone marrow with immunomagnetic beads and with complement and immunoglobulin switch variant mediated cytotoxicity," <i>Leuk Res</i> , 1987, 11: 1119-1125.
	FFFR —	Konstantinov SM et al., "Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines," 2002, <i>J Cancer Res Clin Oncol</i> , 128(5):271-278.
	GGGR ✓	Ledbetter JA et al., "Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency," <i>Circ Shock</i> , 1994, 44: 67-72.

HHHR	Leget GA et al., "Use of rituximab, the new FDA-approved antibody," <i>Curr Opin Oncol</i> , 1998, 10: 548-551.
IIIR	Linderth et al., "Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study," 2003, <i>Clin Cancer Res</i> , 9(2):722-728.
JJJR	Lopez-Matas M et al., "Quantitative expression of CD23 and its ligand CD21 in chronic lymphocytic leukemia," 2000, <i>Hematologica</i> , 85:1140-1145.
KKKB	Maloney DG et al., "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma," <i>Blood</i> , 1997, 90: 2188-2195.
LLLR	Maloney DG et al., "Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies," <i>Oncology (Huntingt)</i> , 1998, 12: 63-76.
MMMR	Matutes E et al., "Morphological and immunophenotypic features of chronic lymphocytic leukemia," 2000, <i>Rev Clin Exp Hematol</i> 4:22-47.
NNNR	McLaughlin P et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program," <i>J Clin Oncol</i> , 1998, 16: 2825-2833.
OOOR	McLaughlin P et al., "Clinical status and optimal use of rituximab for B-cell lymphomas," <i>Oncology (Huntingt)</i> , 1998, 12: 1763-9; discussion 1769-70, 1775-1777.
PPPR	Metkar SS et al., "CD40-ligation-mediated protection from apoptosis of a Fas-sensitive Hodgkin's-disease-derived cell line," <i>Cancer Immunol Immunother</i> , 1998, 47:104-112.
QQQR	Molica S et al., "Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis," 1996, <i>Hematologica</i> , 81:428-433.
RRRR	Montserrat E et al., "Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectives," <i>J Intern Med Suppl</i> , 1997, 740: 63-67.
SSSR	Murphy WJ et al., "Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes," <i>Blood</i> , 1995, 86: 1946-1953.
TTTR	Nakamura T et al., "In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain," <i>Int J Immunopharmacol</i> , 2000, 22: 131-141.
UUUR	Nguyen DT et al., "IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients," <i>Eur J Haematol</i> , 1999, 62: 76-82.
VVVR	Nishida S et al., "Apoptosis-inducing effect of a new bisphosphonate, YM529, on various hematopoietic tumor cell lines," 2003, <i>Biol Pharm Bull</i> , 26(1):96-100.
WWWR	Ohnishi K et al., "[New antitumor drugs for non-Hodgkin's lymphoma]," <i>Gan To Kagaku Ryoho</i> , 1998, 25: 2223-2228.
XXXR	Pedersen IM et al., "The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism," <i>Blood</i> , 2002, 99: 1314-1319 (abstract only).
YYR	Piro LD et al., "Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma," <i>Ann Oncol</i> , 1999, 10: 655-661.
ZZR	Plumas J et al., "Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis," <i>Blood</i> , 1998, 91: 2875-2885.
AAAAR	Nitschke L et al., "CD22 is a negative regulator of B-cell receptor signalling," <i>Curr Biol</i> , 1997, 7: 133-143.
BBBBR	Pene J et al., "IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2," <i>Proc Natl Acad Sci USA</i> , 1988, 85: 6880-6884.
CCCCR	Pozzato G et al., "Effects of alpha-interferon and steroids on CD23 expression and release in B-cell chronic lymphocytic leukemia," <i>Haematologica</i> , 1994, 79: 205-212.
DDDDR	Press OW et al., "Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody," 1989, 7(8):1027-1038
EEEEER	Press OW et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> , 1987, 69: 584-591.
FFFFR	Ravetch JV et al., "Fc receptors," <i>Annu Rev Immunol</i> , 1991, 9: 457-492.
GGGGR	Rector E et al., "Detection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry," <i>Immunology</i> , 1985, 55: 481-488.
HHHR	Reff ME et al., "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20," <i>Blood</i> , 1994, 83: 435-45.



IIIR	Remstein ED et al., "Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells," 2003, <i>Semin Oncol</i> , 30(2):182-186.
JJJR	Renard N et al., "Demonstration of functional CD40 in B-lineage acute lymphoblastic leukemia cells in response to T-cell CD40 ligand," <i>Blood</i> , 1996, 87: 5162-5170.
KKKR	San Miguel JF et al., "Immunophenotypic analysis of Waldenstrom's macroglobulinemia," 2003, <i>Semin Oncol</i> , 30(2):187-195.
LLLLR	Sarfati M et al., "Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia," <i>Blood</i> , 1988, 71: 94-98.
MMMR	Schattner EJ et al., "Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity," <i>Blood</i> , 1998, 91: 2689-2697.
NNNR	Sherr E et al., "Binding the low affinity Fc epsilon R on B cells suppresses ongoing human IgE synthesis," <i>J Immunol</i> , 1989, 142: 481-489.
OOOR	Smiers FJ et al., "CD20 and CD40 mediated mitogenic responses in B-lineage acute lymphoblastic leukaemia," <i>Br J Haematol</i> , 1996, 93: 125-130.
PPPR	Stamenkovic I, et al., "The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion," <i>Nature</i> , 1990, 345: 74-77.
QQQR	Stamenkovic I et al., "The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, CD75, on B cells," <i>Cell</i> , 1991, 66: 1133-1144.
RRRR	Tallman MS, "Monoclonal antibody therapies in leukemias," <i>Semin Hematol</i> , 2002, 39: 12-19 (abstract only).
SSSR	Tutt AL et al., "Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors," <i>J Immunol</i> , 1998, 161: 3176-3185.
TTTT	Valle A et al., "Activation of human B lymphocytes through CD40 and interleukin 4," <i>Eur J Immunol</i> , 1989, 19: 1463-1467.
UUUR	Wang Z et al., "Induction of bcl-x by CD40 engagement rescues slg-induced apoptosis in murine B cells," <i>J Immunol</i> , 1995, 155: 3722-3725.
VVVR	White LJ et al., "Inhibition of apoptosis in a human pre-B-cell line by CD23 is mediated via a novel receptor," <i>Blood</i> , 1997, 90: 234-243.
WWWR	Wohlschlaeger CH et al., "Aberrant immunophenotypes of mantle cell lymphomas," 2003 <i>Leuk Lymphoma</i> , 44(2):269-273.
XXXXR	Worm M et al., "CD40 ligation induces lymphotoxin alpha gene expression in human B cells," <i>Int Immunol</i> , 1994, 6: 1883-1890.
YYYYR	Younes A et al., "Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia," <i>Br J Haematol</i> , 1998, 100: 135-141 (abstract only).
ZZZR	Zhu et al., "Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma," 2002, <i>Br J Haematol</i> , 119(4):905-915.

Examiner	Date Considered:
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>	